Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-News: Wieder Verdopplung? Montag massiver Turnaround und komplette Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MZH8 | ISIN: AU000000ACW3 | Ticker-Symbol: 3AC
Frankfurt
28.03.25
08:06 Uhr
0,018 Euro
-0,001
-5,26 %
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
ACTINOGEN MEDICAL LIMITED Chart 1 Jahr
5-Tage-Chart
ACTINOGEN MEDICAL LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0200,02112:20
0,0200,02128.03.

Aktuelle News zur ACTINOGEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoACTINOGEN MEDICAL LIMITED: ACW conducts Type C meeting with FDA regarding depression-
MiACTINOGEN MEDICAL LIMITED: Actinogen presentation to ASX small & mid-caps conference1
MoACTINOGEN MEDICAL LIMITED: Appendix 3Ys x 5-
MoACTINOGEN MEDICAL LIMITED: Notification of cessation of securities - ACW1
MoACTINOGEN MEDICAL LIMITED: Notification of cessation of securities - ACW2
MoACTINOGEN MEDICAL LIMITED: Application for quotation of securities - ACW1
14.03.ACTINOGEN MEDICAL LIMITED: Results of Meeting1
ACTINOGEN Aktie jetzt für 0€ handeln
04.03.ACTINOGEN MEDICAL LIMITED: Notification of buy-back - ACW-
27.02.Actinogen's Xanamem in 2025 - what's happening?2
24.02.Actinogen reports busy 6 months as development of Xanamem molecule ramps up1
24.02.ACTINOGEN MEDICAL LIMITED: ACW HY25 results Advancing to latestage clinical development1
24.02.ACTINOGEN MEDICAL LIMITED: Actinogen HY2025 financial report and Appendix 4D1
13.02.Actinogen Medical - XanaMIA Phase IIb/III study marches on249Actinogen Medical continues to make progress with its 36-week XanaMIA Phase IIb/III study assessing Xanamem in patients with biomarker-positive mild-to-moderate Alzheimer's disease (AD). The company...
► Artikel lesen
12.02.Actinogen Medical Limited: Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal132Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder ...
► Artikel lesen
10.02.ACTINOGEN MEDICAL LIMITED: Letter to Shareholders, Notice of GM & Proxy Form2
06.02.ACTINOGEN MEDICAL LIMITED: Peer-reviewed clinpharm manuscript published1
30.01.ACTINOGEN MEDICAL LIMITED: Application for quotation of securities - ACW1
27.01.ACTINOGEN MEDICAL LIMITED: ACW December 2024 quarterly activity report & Appendix 4C-
24.01.Actinogen Medical - executive interview364Actinogen Medical is an ASX-listed Australian biotech developing its lead asset, emestedastat (Xanamem), a specific and selective 11ß-HSD1 inhibitor designed to prevent excess cortisol production in...
► Artikel lesen
16.01.Actinogen boosts trial with Cambridge Cognition's digital suite3
Seite:  Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1